Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

Brexit Could Make UK A 'Second-Tier State' For Innovative New Drugs, Business Committee Warns

A report from the UK House of Commons business committee on its inquiry into the impact of Brexit on the pharma sector has flagged up the multiple challenges facing companies and regulators.
Brexit Approvals

EMA Panel Finalises Safety Probe Into Richter’s Fibroid Drug Esmya

Gedeon Richter’s uterine fibroid drug, Esmya (ulipristal acetate), is expected to be the subject of a safety recommendation by the EMA’s pharmacovigilance committee this week.

Drug Safety Europe

Greater Acceptance Of Extrapolation & Switching Boosts Biosimilars But Barriers Remain, Says Sandoz Exec

The biosimilars market is being boosted as physicians become more accepting of biosimilar switching and more willing to prescribe biosimilars on the basis of extrapolation of indications,. However, barriers – including misinformation – remain, as Carol Lynch, president of Sandoz US and chair of the biosimilar medicines group at Medicines for Europe, tells the Pink Sheet.


Biosimilars Europe

More New EU Drug Approvals Bring Total For Year To 14

Seven new drugs were approved in the EU in the March-April period this year: TiGenix/Takeda's Alofisel, BioCryst's Alpivab, Chiesi's Lamzede, AstraZeneca's Lokelma, Pfizer's Mylotarg, GSK's Shingrix and MSD's Steglatro.


Approvals Europe

Price Cuts On MS Drugs Lead UK's NICE To Reverse Earlier Rejection

Avonex, Copaxone, Extavia and Rebif have all been recommended for use on England's National Health Service after their prices were reduced to improve their cost-effectiveness. However, Betaferon remains too expensive to be given a positive recommendation, according to the health technology assessment body, NICE.
Health Technology Assessment United Kingdom

EU Legal Opinion In Truvada Case Could Complicate SPC Grant Process

In one of several cases under way regarding the criteria for awarding supplementary protection certificates, an advocate general of the Court of Justice of the EU has come up with some new legal tests that experts say could make it more difficult to obtain SPCs in certain circumstances.
Intellectual Property Legal Issues
See All